InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET | Source: InveniAI LLC InveniAI LLC Guilford, Connecticut, UNITED STATES
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseases
Dr. Alesci’s proven track record in optimizing early-stage drug development of multiple programs in various therapeutic areas will be key as the company leverages its AI-platform to advance and diversify its portfolio
GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) InveniAI
® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the appointment of Sa